News Center
Share the latest news with you
Partnership
2021-06-17
In June 2023, IMPACT entered into a global license and collaboration agreement with Eikon Therapeutics for PARP1 selective inhibitors including IMP1734. Eikon received an exclusive license from IMPACT to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China.
In December 2023, IMPACT entered into commercial partnership with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, a subsidiary of Huadong Medicine Co., Ltd (SZ.000963) for promoting Senaparib. Huadong Medicine received exclusive promotion rights of Senaparib in mainland China.
We intend to continue exploring partnerships through strategic collaborations including licensing arrangements, co-development and co-commercialization arrangements to maximize the clinical and commercial value of our drug candidates.
Our Science
News Recommendation
Copyright (c) 2013 IMPACT Therapeutics. All Rights Reserved 沪ICP备2024107649号 互联网药品信息证书编号:(沪)-非经营性-2025-0012 /Clinical Trial Privacy Notice / Privacy Notice / Legal Statement
